ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.036,10
-0,07%
S&P 500
5.987,37
0,30%
US Dollar vs BRL
5,8077
0,13%
Bitcoin
92.542,44
-0,56%
Brent Oil
72,755
0,21%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. AMEX
  6. Synvista Therapeutics, (SYI)

  7. Synvista Therapeutics, (SYI) Notícias

SYI

S.Y. Bancorp (SYI)

Synvista Therapeutics,
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:AMEX:SYI
DataHoraFonteTítuloCódigoCompanhia
16/03/200907:00Edgar (US Regulatory)Notice of Effectiveness (EFFECT)AMEX:SYISynvista Therapeutics,
12/03/200914:48Edgar (US Regulatory)Post-Effective Amendment to Registration Statement (POS AM)AMEX:SYISynvista Therapeutics,
12/03/200907:03Edgar (US Regulatory)Post-Effective Amendment to an S-8 filing (S-8 POS)AMEX:SYISynvista Therapeutics,
09/03/200913:25Edgar (US Regulatory)Withdrawal of Registration Statement (RW)AMEX:SYISynvista Therapeutics,
09/03/200913:24Edgar (US Regulatory)-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)AMEX:SYISynvista Therapeutics,
26/02/200915:00Edgar (US Regulatory)Current report filing (8-K)AMEX:SYISynvista Therapeutics,
24/02/200918:15PR Newswire (US)Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSEAMEX:SYI
28/01/200919:00PR Newswire (US)Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business UpdateAMEX:SYI
12/01/200911:30PR Newswire (US)Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for AlagebriumAMEX:SYI
24/12/200816:24PR Newswire (US)Synvista Notified by NYSE Alternext of Continued Listing Standards Non-ComplianceAMEX:SYI
16/12/200811:30PR Newswire (US)Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with DeclineAMEX:SYI
15/12/200811:30PR Newswire (US)Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for PsoriasisAMEX:SYI
03/12/200819:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:SYISynvista Therapeutics,
19/11/200812:43PR Newswire (US)Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test KitAMEX:SYISynvista Therapeutics,
14/11/200818:57Edgar (US Regulatory)Quarterly Report (10-Q)AMEX:SYISynvista Therapeutics,
11/11/200811:30PR Newswire (US)Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA MAMEX:SYISynvista Therapeutics,
10/11/200814:57PR Newswire (US)Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare ConferenceAMEX:SYISynvista Therapeutics,
10/11/200811:30PR Newswire (US)Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the AmeriAMEX:SYISynvista Therapeutics,
24/10/200814:10PR Newswire (US)Synvista Therapeutics to Present at the 2008 BIO Investor ForumAMEX:SYISynvista Therapeutics,
10/10/200817:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:SYISynvista Therapeutics,
10/10/200817:07PR Newswire (US)Synvista Therapeutics Appoints William Federici to its Board of DirectorsAMEX:SYISynvista Therapeutics,
29/09/200810:03PR Newswire (US)Synvista Therapeutics Receives Approval to Begin Phase 2 Trial of Topical SYI-2074 in PsoriasisAMEX:SYISynvista Therapeutics,
17/09/200814:27PR Newswire (US)Synvista Therapeutics Posts Letter to Stockholders on Web SiteAMEX:SYISynvista Therapeutics,
15/09/200810:15PR Newswire (US)Vista Partners Updates Coverage on Synvista Therapeutics, Inc. (Amex: SYI); Maintains $4.46 Target PriceAMEX:SYISynvista Therapeutics,
11/09/200809:00PR Newswire (US)Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in PatientAMEX:SYISynvista Therapeutics,
14/08/200810:29Edgar (US Regulatory)Synvista Therapeutics, Inc. - Quarterly Report (10-Q)AMEX:SYISynvista Therapeutics,
25/07/200807:04Edgar (US Regulatory)Synvista Therapeutics, Inc. - Current report filing (8-K)AMEX:SYISynvista Therapeutics,
24/07/200812:44Edgar (US Regulatory)Synvista Therapeutics, Inc. - Statement of Changes in Beneficial Ownership (4)AMEX:SYISynvista Therapeutics,
06/06/200814:30PR Newswire (US)Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular DiseAMEX:SYISynvista Therapeutics,
04/06/200813:28Edgar (US Regulatory)Synvista Therapeutics, Inc. - Additional Proxy Soliciting Materials (definitive) (DEFA14A)AMEX:SYISynvista Therapeutics,
 Apresentando as notícias mais relevantes sobre:AMEX:SYI

Seu Histórico Recente

BOV
COGN3
COGNA ON
BOV
IBOV
Índice Bovespa
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
TELB4
TELEBRAS PN
BOV
ATOM3
ATOMPAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER PLUS

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 1475.65 apenas $ 590.25